Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, double-blind, randomized, placebo-controlled, parallel-group phase III study for validation of vaccine efficacy of KD-414 (XBB.1.5) in healthy children aged 6 months to less than 13 years

Next Previous
Search
Trial Profile

A multicenter, double-blind, randomized, placebo-controlled, parallel-group phase III study for validation of vaccine efficacy of KD-414 (XBB.1.5) in healthy children aged 6 months to less than 13 years

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KD 414 (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use

Most Recent Events

  • 23 Oct 2023 New trial record
  • 16 Oct 2023 According to Meiji Holdings media release, the development of KD-414, including the abovementioned clinical trial, is partially funded by the Ministry of Health, Labour and Welfare of Japan (MHLW) and by the Japan Agency for Medical Research and Development (AMED).
  • 13 Oct 2023 According to Meiji Holdings media release, KM Biologics Co., Ltd. and Meiji Seika Pharma Co., Ltd. submitted a clinical trial notification to the Pharmaceuticals and Medical Devices Agency (PMDA)for this trial; After the examination of the clinical trial notification by PMDA and the review by the Institutional Review Board of the medical institution implementing the clinical trial, company will start enrolling subjects and vaccine administration from December 2023

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top